Introduction
The diagnosis of large vessel vasculitis remains a challenge, especially in patients presenting with nonspecific symptoms and laboratory tests [1] [2] [3] . Standard diagnostic procedures include biopsy, angiography, ultrasound and magnetic resonance angiography. These procedures are either invasive, operator dependent or detect only morphological changes which mainly occur in later stages of the disease [4] [5] [6] [7] [8] [9] .
Positron emission tomography (PET) is an operatorindependent, noninvasive metabolic imaging modality based on the regional distribution of the glucose analogue 18 F-fluorodeoxyglucose (FDG). Today, 18 F-FDG PET plays a major role in the management of oncology patients [10] . However, activated inflammatory cells also overexpress glucose transporters and accumulate increased amounts of glucose and structurally related substances such as 18 F-FDG [11, 12] .
Remarkable images of patients with active vasculitis have been generated through 18 F-FDG PET scans [13] [14] [15] and initial studies indicated that 18 F-FDG PET might become useful for imaging giant cell arteritis [16] and Takayasu's arteritis [17] . Large vessel involvement is found by 18 F-FDG PET in about 83% of patients with giant cell arteritis [18] . Thereby, vascular FDG uptake is found especially in the subclavian arteries (74%), but also in the aorta (≥50%) and up to the femoral arteries (37%). The common 18 F-FDG uptake pattern found in giant cell arteritis is linear and continuous and thoracic vessels are most frequently affected, followed by the abdominal vessels [19, 20] . The common 18 F-FDG uptake pattern in early phases of Takayasu's arteritis is linear and continuous, while in late phases it becomes rather patchier than continuous [21] . Recent 18 F-FDG PET studies have shown sensitivities between 56 and 100% for detecting giant cell arteritis and sensitivities between 83 and 100% for detecting Takayasu's arteritis [22] [23] [24] . Comparative studies employing 18 F-FDG PET and magnetic resonance imaging revealed comparable sensitivities of both methods, but 18 F-FDG PET has been shown to identify significantly more affected vascular regions [19, 25] . Furthermore, 18 F-FDG PET has shown a value for predicting the development of complications, e.g. thoracic aortic dilatation in patients with giant cell arteritis [26] , and the ability to demonstrate response after successful initiation of immunosuppressive treatment [18] . Nevertheless, the diagnostic accuracy that 18 F-FDG PET adds to the diagnostic workup as well as its impact on the clinical management has not been systematically evaluated yet.
This study therefore aimed to explore the diagnostic accuracy of 18 F-FDG PET on its own and as an add-on test to the conventional workup as well as its impact on the clinical management in patients with suspected large vessel vasculitis.
Materials and methods
A panel of international experts in the field of large vessel vasculitis determined diagnoses and clinical management in patients with suspected large vessel vasculitis, with and without the results of the 18 F-FDG PET scan, respectively. The accuracy of the clinical diagnosis and the resulting clinical management with and without the 18 F-FDG PET results were compared. The study was approved by the local Ethics Committee (www.ekbb.ch, reference number 18/10). Because we used archived patient data the study was deemed exempt from requiring consent.
Patients
We included patients with (1) suspected large vessel vasculitis who (2) were referred to our interdisciplinary tertiary referral centre of the Department of Rheumatology, University Hospital Basel, Switzerland and who (3) had received a whole-body PET at the Department of Nuclear Medicine, University Hospital Basel, (4) (Fig. 1) . 18 
F-FDG PET imaging
All scans were acquired after a 12-h fast with a dedicated fullring PET camera system. Serum glucose levels were measured before 18 F-FDG application in all patients and were below 180 mg/dl (Glucometer Elite®, Bayer Diagnostics, UK).
Image acquisition was started 45 min after intravenous injection of 5 MBq/kg body weight of 18 F-FDG with the patient in the supine position. Iterative reconstruction of the transaxial slices was performed using the ordered subset expectation maximization (OSEM) algorithm (2 iterations, 8 subsets).
All scans were assessed by a panel of a board certified nuclear medicine physician, a board certified radiologist and a physician board certified in nuclear medicine and radiology (M.A.W., S.B. and H.R.). The panel was blinded to the patients' initial clinical, laboratory and imaging results as well as to the follow-up data. The images were judged as positive or negative for large vessel vasculitis as previously described [20] : The severity of large vessel 18 F-FDG uptake was visually graded using a 4-point scale: 0 = no uptake present, I = low-grade uptake (uptake present but lower than liver uptake), II = intermediate-grade uptake (similar to liver uptake) and III = high-grade uptake (uptake higher than liver uptake). Considering grade II or III uptake in the thoracic aorta and any visible uptake in other segments as pathological due to an active arterial inflammation has previously shown a high sensitivity for large vessel vasculitis [20] . Each expert scored (1) the probability of large vessel vasculitis (in per cent) and based on the average score patients were judged as disease positive (probability 67-100%), negative (0-33%) and intermediate (34-66%). Furthermore, each expert (2) recommended further diagnostic workup from a panel of predetermined options including laboratory, ultrasound, computed tomography, magnetic resonance imaging and biopsy and (3) scored the disease extent and activity, each ranging from 1 (minimal) to 10 (maximal) or "indeterminable" and finally (4) the recommended drug management, e.g. in untreated patients to start or not to start glucocorticosteroids and/or other immunosuppressive drugs and in already treated patients to escalate or reduce the immunosuppression.
Study endpoints
The predefined study endpoints were (1) the diagnostic accuracy of 
Statistical analyses
Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of the clinical scoring with and without 18 F-FDG PET results were calculated using the expert panel assessment as the reference standard. Differences in proportions were tested with the χ 2 or Fisher's exact test, as appropriate. Logistic regression models were used to examine the association of the pre-PET disease probability with the probability of 18 F-FDG PET ruling out or confirming disease. Logistic regression was also used to examine the association of disease probability and the indication of biopsy.
Sensitivity analyses were performed to evaluate the effects described above in the subgroup of patients with giant cell arteritis.
All discrete variables are described by counts (percentage) and continuous variables by their median (range), unless stated otherwise. Two-sided p values of <0.05 were considered to indicate statistical significance.
Results
Overall, 67 patients were considered for inclusion. Of these, large vessel vasculitis was confirmed in 30 (44.8%; 24 giant cell arteritis, 6 Takayasu's arteritis) and ruled out in 31 (46.3%). Six patients (8.9%) with inconclusive follow-up data were excluded from the study (Fig. 1) (Table 2 ). In the subgroup of patients with giant cell arteritis the diagnostic accuracy was 81.8%. All eight false-negative 18 F-FDG PET scans were performed under immunosuppressive drugs (Fig. 2) .
The diagnostic value of 18 F-FDG PET with and without immunosuppressive drugs In 30 patients without immunosuppressive drugs, 13 scans were truly positive, 2 were falsely positive, 15 were truly negative and none were falsely negative. The resulting sensitivity was 99.6% (95% CI 69.8-100%), the specificity was 86.1% (95% CI 58.6-96.4%), the positive predictive value was 84.4% (95% CI 54.4-96.0%) and the negative predictive value was 99.6% (95% CI 73.2-100%). The diagnostic accuracy of 18 F-FDG PET in patients without immunosuppressive drugs was 93.3% (28 of 30 patients were labelled correctly, Table 2 ).
In the 31 patients on immunosuppressive drugs on the other hand, 9 scans were truly positive, 3 were falsely positive, 11 were truly negative and 8 were falsely negative. The resulting sensitivity was 52.9% (95% CI 27.8-77.0%), the specificity was 78.6% (95% CI 49.2-95.3%), the positive predictive value was 75.0% (95% CI 42.8-94.5%) and the negative predictive value was 57.9% (95% CI 33. Table 2 ).
The detailed expert scoring results are presented in Fig. 6 of the Appendix.
The addition of the 18 F-FDG PET results changed the diagnosis in 18 patients (27.9%): 14 times from an intermediate probability or incorrect diagnosis to the correct diagnosis, 2 times from the correct diagnosis to an intermediate probability and 2 times from the correct diagnosis to a wrong diagnosis. Overall, the addition of the 18 F-FDG PET result reduced the number of patients scored undetermined from 20 to 10.
Of 30 disease-positive patients 25 (83.3%) were identified correctly, 3 (10.0%) were falsely scored disease negative, while 2 (6.7%) were scored as intermediate probability. Of the 31 disease-negative controls 18 (58.1%) were correctly identified as disease negative, 5 (16.1%) were falsely scored as disease positive, while 8 (25.8%) were scored as undetermined. With the 18 F-FDG PET results, 43 of 61 patients were diagnosed correctly (diagnostic accuracy 70.5%), significantly more than without the 18 F-FDG PET data (p=0.04). In the subgroup of patients with giant cell arteritis the addition of the 18 F-FDG PET results increased the diagnostic accuracy from 50.9 to 69.1% (p=0.05).
18 F-FDG PET had a higher additional diagnostic value in confirming than in ruling out large vessel vasculitis. In disease-positive patients, the addition of 18 F-FDG PET significantly changed the scored probability of disease from a median of 62.2% (range 20.6-97.4%) to Fig. 3 ). On the contrary, in the disease-negative controls the addition of the 18 F-FDG PET results did not significantly change the scored probability [25.6% (0.8-88.3%) to 16.7% (1.8-93%), p= 0.65, Fig. 3 ]. Overall, 10 patients were scored as undetermined The impact of 18 
F-FDG PET on the biopsy recommendation
With all the diagnostic workup data available except the 18 F-FDG PET results, biopsy was scored to be indicated in 22 patients (36.1%). The addition of the 18 F-FDG PET results changed the biopsy indication from 'yes' to 'no' in four patients and from 'no' to 'yes' in seven patients. As a result, the addition of the 18 F-FDG PET results did not significantly change the number of patients with indicated biopsy to 25 (41.0%, Fig. 4a ). Logistic regression revealed a positive correlation of higher biopsy rates when higher probabilities of large vessel vasculitis were scored (Fig. 4b) .
The impact of 18 F-FDG PET on treatment recommendation
The impact of 18 F-FDG PET on the medical management was assessed in patients receiving and not receiving immunosuppressive medication.
Of all 61 patients, 30 (49.2%) had not received any immunosuppressive medication. With all diagnostic workup data available except the 18 F-FDG PET results, glucocorticosteroids were considered to be indicated in 11 of the 30 patients, while no change in management was recommended in 19 patients. The addition of the 18 F-FDG PET result changed the indicated management in eight patients (26.7%, Fig. 5a ). Four patients were changed from no drugs to corticosteroids, one patient was changed from no drugs to corticosteroids with additional immunosuppressives, while three patients were changed from corticosteroids to corticosteroids with additional immunosuppressives.
Thirty-one patients (50.8%) were receiving immunosuppressive medication. Without the 18 F-FDG PET results, a dose increase was scored to be indicated in 3, a decrease to be indicated in 7, while no change in management was indicated in 21 patients. The addition of the 18 F-FDG PET results changed the management in seven patients (22.6%, Fig. 5b ). Two patients were shifted from 'no change' to 'dose increase' and five patients were shifted from 'no change' to 'dose decrease'. In total, 18 F-FDG PET changed the treatment recommendation in 15 patients. In 8 of these 15 patients (53.3%) the 18 F-FDG PET had also changed the overall diagnosis.
Discussion
The present results indicate that 18 F-FDG PET is a sensitive and specific imaging tool that increases the overall diagnostic accuracy for large vessel vasculitis in the context of the available diagnostic results. Thereby, 18 F-FDG PET has an impact on the medical management in a significant proportion of patients.
The sensitivities and specificities found are comparable to previously published results [22] . The underlying principle of PET imaging in inflammatory processes is the increased accumulation of glucose and structurally related substances such as 18 F-FDG into inflammatory cells [11, 12] . Alternatively, magnet resonance imaging, which is also used for imaging large vessel vasculitis, mainly analyses the thickness of the vascular wall [27] . We have previously shown that the accuracy of 18 F-FDG PET increases in the state of active inflammation [20] . In line with these results, previous studies have indicated a lower diagnostic value of 18 F-FDG PET in patients with suspected large vessel vasculitis under immunosuppressive drugs [28, 29] . The present study systematically evaluated the diagnostic accuracy of 18 F-FDG PET with and without immunosuppressive medication and found a significantly reduced diagnostic value in patients on immunosuppressive drugs. Consequently, 18 F-FDG PET should, whenever feasible, be performed in an interval without immunosuppressive drugs.
Until now it has remained elusive whether adding 18 F-FDG PET results to the usual diagnostic workup for large vessel vasculitis would increase diagnostic accuracy. Here, the present study showed that 18 F-FDG PET allows the overall accuracy of the diagnostic workup to be significantly increased. Furthermore, the present results showed that 18 F-FDG PET principally had a higher value in confirming than ruling out disease. The increase of diagnostic accuracy by 18 F-FDG PET is relevant to the diagnostic workup of each individual patient as well as to the current efforts to establish diagnostic and classification criteria for systematic vasculitis [2] . 18 F-FDG PET changed the indicated medical management in both groups, patients with and without immunosuppressive drugs, respectively. Thereby, with changes in management in about one of four patients, the extent of the influence of 18 F-FDG PET was similar in both groups. These results demonstrate that 18 F-FDG PET increases diagnostic accuracy and changes medical management in a significant proportion of patients.
One of the aims of noninvasive PET imaging is to provide a whole-body status and to replace local invasive procedures such as biopsies. In this study, the addition of 18 F-FDG PET did not decrease the frequency of recommended biopsies despite the increased diagnostic value. We found a positive correlation between the probability of larger vessel vasculitis and the probability of recommendation for biopsy. Higher pre-test probabilities increased the rate of recommended biopsies. These results indicate that, given the current state of evidence, 18 F-FDG PET is unlikely to replace biopsy procedures in the near future.
This study has strengths and limitations. First, large vessel vasculitis is a rare condition and accordingly the present cohort is relatively small. Nevertheless, the study was sufficiently powered to obtain significant results. Secondly, the present study shows that 18 F-FDG PET increases the diagnostic accuracy of experts in the field of large vessel vasculitis that scored the disease probability on a scale from 0 to 100%, analogous to the visual analogue scale [30] . The effect on the diagnostic accuracy in less experienced physicians remains elusive. Third, the reference standard may be influenced by results of 18 F-FDG PET potentially leading to incorporation bias since the reference panel based its decisions on the complete clinical follow-up of patients including all diagnostic test results. Fourth, the study cohort comprises patients with giant cell arteritis and Takayasu's arteritis. Accordingly, sensitivity analyses were performed that showed similar results in the cohort of giant cell arteritis patients. In accordance with previous studies [31] , we were not able to detect enhanced uptake in temporal vessels. This limitation is mainly due to the high FDG uptake in the brain and the small diameter of the temporal arteries. Next generation PET scanners, however, might be able to reliably measure FDG uptake in temporal vessels. Finally, the study showed that 18 F-FDG PET has an impact on the medical management in a significant proportion of patients. In a next step further studies are warranted to evaluate the potential improvement in the clinical outcome by the additional use of 18 F-FDG PET. Previous studies had already assessed the diagnostic performance of 18 F-FDG PET in patients with and without immunosuppressive medication. The present study is the first to systematically analyse the impact of 18 F-FDG PET on biopsy and treatment recommendations. The results demonstrate the additional diagnostic value of 18 F-FDG PET in patients with suspected large vessel vasculitis and they define the conditions under which 18 F-FDG PET is anticipated to be most helpful. Whenever feasible, 18 F-FDG PET should be performed when the patient is not receiving immunosuppressive drugs. 18 F-FDG PET increases the overall diagnostic accuracy and has an impact on the medical management in a significant proportion of patients. 
